From the Journals

Substantial long-term increase seen in multiple myeloma survival


 

FROM JAMA

The 5-year survival rate for multiple myeloma increased eightfold over an approximately 60-year span starting in the early 1950s, said Ali H. Mokdad, PhD, and his associates.

Patients with multiple myeloma had a 5-year relative survival rate of 6% in 1950-1954, compared with 49.8% in 2008-2013, according to data from the Surveillance, Epidemiology, and End Results Program (JAMA 2017;317[4]:388-406).

Five-year survival up 730% for multiple myeloma
In another part of the study that used deidentified death records from the National Center for Health Statistics and population counts from the Census Bureau, the NCHS, and the Human Mortality Database, mortality for multiple myeloma in 2014 was 3.9 per 100,000 population, putting it 16th among the 29 cancers included in the analysis, the investigators reported.

In 2014, there were about 13,000 deaths resulting from multiple myeloma, with 219,000 years of life lost, which ranked 17th among the 29 selected cancers, noted Dr. Mokdad and his associates at the Institute for Health Metrics and Evaluation at the University of Washington, Seattle.

Recommended Reading

Myeloma precursor linked to Agent Orange exposure
MDedge Internal Medicine
NCCN unveils 'Evidence Blocks' to facilitate treatment discussions
MDedge Internal Medicine
Multiple myeloma advances in diagnosis, staging, therapy extend survival
MDedge Internal Medicine
ASH: Carfilzomib doubles progression free survival in head-to-head trial with bortezomib
MDedge Internal Medicine
VIDEO: Targeted agent, len/dex combo perform ‘impressively’ in advanced multiple myeloma
MDedge Internal Medicine
ASH: All-oral regimen extends multiple myeloma PFS
MDedge Internal Medicine
ASH: Daratumumab and len/dex produce high response rates in refractory myeloma
MDedge Internal Medicine
Lysolipid antigens prominent in MGUS and myeloma
MDedge Internal Medicine
IMWG issues renal impairment recommendations for myeloma patients
MDedge Internal Medicine
FDA approves propylene glycol–free melphalan for multiple myeloma
MDedge Internal Medicine